Office Address:
The Wistar Institute
36th Street at Spruce
Philadelphia, PA 19104
(215) 898-3950
(215) 898-0980 (FAX)
E-mail: herlynm@wistar.org
Web: http://www.wistar.org/herlyn
Education:
1964-1970 D.V.M, Veterinary Medical School,
Hannover, Germany
1976 D.Sc., Medical Microbiology; University
of Munich, Munich, Germany
Postgraduate Training and Fellowship
Appointments:
1971-1972 Fellowship in Immunology and Virology,
University of Munich, Munich, Germany
1972-1976 Assistant at the Institute of
Medical Microbiology, Infectious and Epidemic
Diseases, Veterinary Faculty, University
of Munich, Munich, Germany
1976-1979 Associate Scientist, The Wistar
Institute, Philadelphia, PA
1979-1981 Research Associate, The Wistar
Institute, Philadelphia, PA
1981-1985 Assistant Professor, The Wistar
Institute, Philadelphia, PA
1986-1990 Associate Professor, The Wistar
Institute, Philadelphia, PA
1991-present Professor, The Wistar Institute,
Philadelphia, PA
1991-1993 Chairman, Program of Experimental
Therapeutics, The Wistar Institute
1993-1998 Chairman, Program of Molecular
and Cellular Biology, The Wistar Institute
1998-2002 Chairman, Tumor Biology Program,
The Wistar Institute
2002 Deputy Director pro tempore,
The Wistar Institute
2002-present Leader, Molecular and Cellular
Oncogenesis Program, The Wistar Institute
Professional Experience:
1972-1976 Assistant at the Institute of
Medical Microbiology, Infectious and Epidemic
Diseases, Veterinary Faculty, University
of Munich, Munich, Germany
1976-1979 Associate Scientist, The Wistar
Institute, Philadelphia, PA
1979-1981 Research Associate, The Wistar
Institute, Philadelphia, PA
1981-1985 Assistant Professor, The Wistar
Institute, Philadelphia, PA
1986-1990 Associate Professor, The Wistar
Institute, Philadelphia, PA
1991-present Professor, The Wistar Institute,
Philadelphia, PA
1991-1993 Chairman, Program of Experimental
Therapeutics, The Wistar Institute, Philadelphia,
PA
1993-1998 Chairman, Program of Molecular
and Cellular Biology, The Wistar Institute,
Philadelphia, PA
1998-2002 Chairman, Tumor Biology Program,
The Wistar Institute, Philadelphia, PA
2002 Deputy Director pro tempore, The Wistar
Institute, Philadelphia, PA
2002-present Chairman, Molecular and Cellular
Oncogenesis Program, The Wistar Institute
Faculty Appointments:
1982-1996 Consultant, Adjunct Associate
Professor of Gynecology, Adjunct Professor
of Gynecology, Dept. of Gynecology, Division
of Surgery, University of Texas, M.D. Anderson
Cancer Center, Houston, TX
1989-1991 Wistar Institute Associate Professor
of Dermatology and Wistar Institute Associate
Professor of Pathology and Laboratory Medicine,
University of Pennsylvania, School of Medicine,
Philadelphia, PA
1989-present Member, Cellular and Molecular
Biology Graduate Program (CAMB), University
of Pennsylvania, Philadelphia, PA
1991-present Member, University of Pennsylvania
Comprehensive Cancer Center, Philadelphia,
PA
1992-present Wistar Institute Professor
of Dermatology and Wistar Institute Professor
of Pathology and Laboratory Medicine, University
of Pennsylvania, School of Medicine, Philadelphia,
PA
1995-2002 Member, Institute for Human Gene
Therapy, University of Pennsylvania, School
of Medicine, Philadelphia, PA
Awards, Honors and Membership
in Honorary Societies:
2004 Hungarian Dermatological Society, Honorary
Member
2004 Wings of Hope, Melanoma Research Foundation
Award
2004 Diana Ashby Award for Excellence in
Melanoma Research Award
2005 American Skin Association Annual Skin
Cancer/Melanoma Achievement Award
2006 Seventh Annual Wallace H. Clark, JR.,
MD Lectureship in Cutaneous Oncology
Membership in Professional and Scientific Societies: (Including offices held.)
Editorial Positions:
1986-1988 Editorial Board, The Journal
of Clinical Laboratory Analysis
1990-present Associate Editor, Melanoma
Research
1992-1998 Editorial Board, Cell Growth
and Differentiation
1994-1999 Associate Editor, Pigment
Cell Research
1995-present Associate Editor, Journal
of Experimental Therapeutics and Oncology
1995-present Editorial Board, Pathology
Oncology Research
1997-present Editorial Board, American
Journal of Pathology
1998-2000 Editorial Board, Tumor Targeting
2000-2006 Editorial Board, Cancer Research
2001-present Editorial Board, Cancer
Biology and Therapy
2002-present Editorial Board, Cancer
and Metastasis Reviews
2002-2005 Associate Editor, Journal
of Investigative Dermatology
2005-2008 Associate Editor, Pigment
Cell Research
2005-present Editorial Board, International
Journal of Cancer
Reviewer of 127 manuscripts in 2002, 172 in 2003, 125 in 2004, and 154 in 2005 for: American Journal of Pathology, Archives of Dermatology, Cancer, Cancer Cell, Cancer Research, Cell, Clinical Cancer Research, Experimental Cell Research, International Journal of Cancer, Journal of Cell Science, Journal of Clinical Investigations, Journal of Investigative Dermatology, Journal of Immunology, Journal of Experimental Medicine, Laboratory Investigation, Melanoma Research, Molecular Carcinogenesis, Nature, Nature Medicine, Nature Review Cancer, Oncogene, Pigment Cell Research, Proceedings National Academy of Sciences (USA), Science.
Committee Service at The Wistar
Institute :
1990-present Staff Council
1999-2002 Search Committee, Director
2003-present Search Committees, Staff
2005-present Building and Renovation Committee
Lectures by Invitation (past 5 years):
2002
Jan. 22 L'Oreal, Paris, France
Jan. 25 University of Utah, Salt Lake City,
UT
Jan. 28 Workshop on Melanoma, NIH Study
Section, Keystone, CO, Chair
Jan. 31 Wallace H. Clark Symposium, University
of Pennsylvania, Philadelphia, PA
Febr. 12 NIH Interdisciplinary Pigmentation
Group, Bethesda, MD
March 18 Georgetown University, Washington.
DC
May 8 Hershey Medical Center, Hershey, PA
July 2 World Congress of Dermatology, Paris,
France
Sept. 11 International Pigment Cell Congress,
Egmont-aan-Zee, Netherlands
Sept. 13 Satellite Symposium on Melanoma
Biology, Egmont aan Zee, Netherlands, Chair
Sept. 21 Melanoma Research Foundation, Washington,
DC
Sept.29 Critical Review of Melanoma: Biology
and Therapy, Banbury Center, Cold Spring
Harbor, Chair
Oct 15 Abginix, Freemont, CA
Oct. 31. University of Kentucky, Lexington,
KY
Dec. 3 University of Regensburg, Regensburg,
Germany
Dec. 4 Ludwig Maximilians University, Muenich,
Germany
Dec. 5 University of Tuebingen, Tuebingen,
Germany
Dec. 6 University of Wuerzburg, Wuerzburg,
Germany
2003
March 5 L'Oreal, Paris, France
March 7 UCSF, San Francisco, CA
March 19 University of Toronto, Toronto,
Canada
March 21 Johnson&Johnson, Skillman,
NJ
April 14 University of Arizona, Tuscon,
AZ
April 30 University of Florida, Tampa, FL
May 5-7 Melanoma State of the Science Meeting
‘Melanoma 2003: Turning Scientific Discoveries
into Clinical Targets’, NCI, Bethesda, MD
June 21-24 First International Melanoma
Research Congress, Philadelphia, PA, Organizer
Sept. 16-19
Euroskin Conference, Stockholm, Sweden
Oct. 16-19 Mouse Models of Human Cancer
Consortium, Bismo Beach, CA
Oct. 20 Kobe University, Kobe, Japan
Oct. 21 Japanese Congress for Internal Medicine,
Keynote Speaker, Sapporo, Japan
Oct. 23 Matsumoto University, Tokyo, Japan
Nov. 5-7 Tumor Microenvironment Think-tank,
NCI, Bethesda, MD
Dec. 2-4 European Biotechnology Congress,
Vienna, Austria
2004
Febr. 10 NCI Tissue Conference, Bethesda,
MD
March 4 University of Iowa, Iowa City, IO
March 22 Wyeth Inc., Pearl River, NJ
April 8 NIH/NIDCR, Bethesda, MD
April 16 3D-Pharma/J&J, Exton, PA
April 30 European Skin Cancer Congress,
Budapest, Hungary, Keynote Lecture
May 1 University of Debrecen, Hungary
June 23 Vanderbilt University, Nashville,
TN
July 13 SPORE Meeting, Baltimore, MD
July 25 World Skin Conference, Zuerich,
Switzerland
July 27 IFOM Institute, Milan, Italy
Oct. 15 Montagna Symposium, Corvalis, OR,
Keynote Lecture
Oct. 21 UCSF Cancer Center Symposium, San
Francisco, CA
Nov. 13 Second International Melanoma Research
Congress, Phoenix, AZ, Keynote Lecture
Nov. 30 BRAF signaling, Kloster Banz, Germany
Dec. 7 Mahe University, Marsipal, India
Dec. 15 Harvard Medical School, Boston,
MA
2005
Jan.12 Loyola University, Chicago, IL
Jan. 25 Johns Hopkins University, Baltimore
MD
Feb. 11 Glaxo-Smith-Kline, Philadelphia,
PA
Feb. 28 Tumor microenvironment, TME-NCI
workshop, Washington, DC
March 15 Harvard Medical School, Boston,
MA
March 29 University of Massachusetts, Worcester,
MA
April 18 AACR Annual Meeting, Anaheim CA
April 23 German Dermatological Society,
Dresden, Germany
May 14 World Dermatology Congress, Vienna,
Austria
May 16 World Dermatology Congress, Vienna
, Austria
July 26 Drexel University , Philadelphia
, PA
Sept. 6/8 World Melanoma Congress, Vancouver
, Canada , Session Chair
Sept. 21 International Pigment Cell Congress,
Rayton , VA
Oct. 1 Angiogenesis and Tumor Microenvironment,
Ascona , Switzerland
Oct. 23 Fox Chase Cancer Center , Philadelphia
, PA
Nov.11 Cancer Stem Cells, Milano , Italy
Nov.15 AACR-NCI-EORTC: Molecular Targets,
Philadelphia , PA
Nov. 18 Perspectives in Melanoma, Tampa,
FL
Dec. 6 M.D. Anderson Cancer Center , Houston
, TX
2006
Jan. 9 Bristol-Myers-Squibb, Princeton,
NJ
Jan. 19 Keystone Conference on Melanoma,
Santa Fe, NM
Feb. 5 Timberline Symposium, Mt. Hood, OR
March 7 L’Oreal, Paris, France
March 10 New Frontiers in Cancer Research
and Therapy, Karolinska University Hospital,
Stockholm, Sweden
April 1 American Association for Cancer
Research, Washington, DC
April 10 Burnham Institute, La Jolla, CA
April 27 Wallace H. Clark Memorial Lecture,
Philadelphia, PA
May 11 Focus on Melanoma, Philadelphia,
PA
June 5 American Association for Clinical
Oncology, Atlanta, GA
June 15 Sixth International Conference Adjuvant
Therapy of Malignant Melanoma, Stockholm,
Sweden
June 21 Rush Hospital and Medical Center,
Chicago, IL
June 26 Cellumen, Pittsburgh, PA
June 27 Coriell Institute, Camden, NJ
July 17 SPORE Symphosium on Cancer Stem
Cells, Co-chair, Baltimore, MD
July 18 SPORE Skin Break-out Session, Chair,
Baltimore, MD
Sept. 6 Amgen Inc. Thousand Oaks, CA
Sept. 12 University of Lausanne, Lausanne,
CH
Sept. 15 3rd International Melanoma Research
Congress, Noordwijk, Netherlands
Sept. 18 International Society for Oncodevelopmental
Biology and Medicine, Pasadena, CA
Sept. 19 City of Hope Medical Center, City
of Hope, CA
Advisory Roles (last four years):
2002-present Advisor (since 2000), Program Project on 'Mesothelioma', S. Albelda, P.I., University of Pennsylvania
2002 Advisory Panel, NCI SPORE Program
Jan., NCI Special Emphasis Panel, ad hoc
Jan., NCI Study Section "Pathology
B", ad hoc
March, NCI Special Emphasis Panel, ad hoc
July, NCI Special Emphasis Panel, ad hoc
Sept., NCI Program Project Site Visit, Chair
Dec., NCI Subcommittee D, ad hoc
Cancer Biology Advisory Group, University
of Pennsylvania, Member
2002-2004 Member, Skin Care Council Advisory
Group, Johnson & Johnson, Skillman,
NJ
2003 Feb., NCI Special Emphasis Panels 1
and 2, ad hoc
2003-present SPORE in Skin Cancer, T. Kupper,
P.I., Harvard Medical School, advisor
2003 Sept., Laboratory of Molecular Biology,
NCI, Review Panel, ad hoc
Nov., NCI Fellowship Study Section, ad hoc
Advisory Panel, NCI SPORE Program
2004 Feb., June, Oct., NCI Study Sections,
Tumor Microenvironment (TME), Chair
March, NCI Study Section, TCB, ad hoc
June, NCI Cancer Center Review, ad hoc
July, NCI Special Emphasis Panel, Chair
August, NCI Special Emphasis Panel, Chair
Sept., NCI Intramural Laboratory Review,
ad hoc
October, DOE, Special Review Panel, ad hoc
2004-present SPORE in Skin Cancer, E. Grimm,
P.I., M.D. Anderson Cancer Center, advisor
2004-present SPORE in Breast Cancer, Fox
Chase Cancer Institute, C. Jordan, P.I.,
advisor
2004-present COBRE Grant, Marshall University,
Huntington, VW, R. Miles, PI,
advisor
2004-2007 National Disease Research Interchange
(NDRI), Board of Directors,
Cancer Advisory Committee, Chair
2005 Feb., June, Oct., NCI Study Sections,
Tumor Microenvironment (TME),
Chair
March, NCI Special Emphasis Panels (2),
Chair
June, NCI, PO1 cluster review, ad hoc
July, NCI Special Emphasis Panels (3), Chair
Sept., Melanoma Research Foundation
Nov., NCI RAIDD Program, ad hoc
Nov., NIAMS, SDRC, ad hoc
Feb.-Dec., Reviews for Cancer Panels in
Netherland, Austria, Italy
Israel, Canada, Australia and Ireland
2006 Feb., June, NCI Study Sections, Tumor
Microenvironment (TME),
Chair
Feb.-June Reviews for Cancer Panels in Italy,
Austria, Canada, Switzerland,
Canada
Sept, NCI, Roadmap on Interdisciplinary
Research Collaborations, Special
Emphasis Panel
2006-present Scientific Review Board, GenoMEL
(Melanoma Genetics consortium),
member
External Advisor PO1 ,The system response
to DNA damage suppresses environmental melanomagenesis’,
(W. Kaufman, P.I.), University of North
Carolina, Chapel Hill, NC
Funding:
"Cell-cell Communication during melanoma
progression"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA76674), Years 9-14, Period:
December 5, 1997 to March 30, 2011.
"Experimental transformation of human
melanocytes in vivo"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA80999), Years 1-5, Period:
April 1, 1999 to March 30, 2009.
"Metastasis: Biological Phenotype
and Models for Therapy"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA47159), Years 16-20, Period:
April 1, 2003 to March 31, 2008.
"Human Melanoma: Etiology, Progression,
and Therapy"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: P01-Program Project (CA25874), Years
25-29, Period: April1, 2005 to March 31,
2010.
Subproject 1 (Meenhard Herlyn): "The
microenvironment in melanoma development
and progression".
"Skin Cancer"
Director: Meenhard Herlyn
Agency: National Cancer Institute
Type: P50-SPORE [Specialized Program of
Research Excellence] (CA93372), Years 1-7,
Period: Oct. 1, 2001 to June 30, 2009.
Project 3 (David Elder and Meenhard Herlyn,
Co-Leaders): “Gene expression of experimentally
induced human melanocytic lesions to define
new markers for atypical nevi and primary
melanomas from patients”.
"Mechanisms of esophageal carcinogenesis"
Principal Investigator: Anil Rustgi, Co-Principal
Investigator: Meenhard Herlyn
Type: P01-CA098101, Years 1-5, 2003-2008
Project 2 (Meenhard Herlyn): “Epithelial-stromal
interactions in normal esophagus homeostasis
and tumor development”.
“Second International Melanoma Research
Congress”
Principal Investigator: Meenhard Herlyn
Type: R13-CA101927, 2003-2004.
NCI-sponsored Tumor Microenvironment Training
Site: Techniques in the Establishment and
Manipulation of Organotypic Model Systems
Principal Investigator: Meenhard Herlyn
Agency:NIH/NCI
Type: Contract, August 2005-July 2007
A new program to train established and new NCI-funded investigators (or nominated post-doctoral fellows in their laboratories) in establishing, maintaining, manipulating and characterizing a variety of organotypic and/or orthotopic models of human cancer.
N/A (Dr. M. Herlyn), October /05-December
2006
GlaxoSmithKline
Development of Spheroid Technology
N/A (Dr. M. Herlyn), 2003 - 2006
SULLIVAN FOUNDATION
Melanoma Research
“The stromal environment for normal and
malignant cells”
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: U54 Tumor Microenvironment Netwerk,
pending
Subproject 1 (Meenhard Herlyn) “The stromal
environment for normal and malignant melancyte
stem cells”
"Targeted therapies in melanoma"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: P01-Program Project, pending
Subproject 1 (Meenhard Herlyn): "Targeting
the MAPK and PI3K pathways".
Core Activities:
1.”Administrative Core A" for Melanoma Program Project, CA 25874, M. Herlyn P.I., 1990-2010.
2.”Administrative Core A" for SPORE on Skin Cancer, CA93372, M. Herlyn, P.I., 2001-2009.
3. “Administrative Core A" for PO1 on Targeted Therapies in Melanoma, Pending, M. Herlyn, P.I.,
4. Administrative Core A" for SPORE on Skin Cancer, CA93372, M. Herlyn, P.I., 2001-2009.
5. Developmental Research Projects for SPORE on Skin Cancer, CA93372, M. Herlyn, P.I., 2001-2009.
6."Cell Biology Core C" for Melanoma Program Project, CA 25874, M. Herlyn P.I., 1990-2010.
7."Cell Culture" for Center for Molecular Studies in Digestive and Liver Disease, P30 DK50306. A. Rustgi, P.I., 2001-2006.
8. "Cell Biology Core C" for PO1 ‘Targeted therapy in melanoma”, pending.
Books:
Molecular and cellular biology of melanoma,
by Herlyn, M., R. G. Landes Co., Austin,
TX, 1993
Patents:
1. Detection of Colorectal Carcinoma
U.S. Patent # 4,471,057
Issued: September 11, 1984
Inventors: Hilary Koprowski, Zenon Steplewski,
and Meenhard Herlyn
2. Lewis Blood Group Phenotype Assay
U.S. Patent # 4,607,009
Issued: August 19, 1986
Inventors: Zenon Steplewski, Hilary Koprowski,
and Meenhard Herlyn
3. Monoclonal Anti-Ornithine Decarboxylase
Antibody and Method of Producing Same
U.S. Patent # 4,637,984
Issued: January 20, 1987
Inventors: Thomas O'Brien, Anthony Pegg,
and Meenhard Herlyn
4. Diagnostic Method for Detection of Neural
Crest Disease
U.S. Patent # 4,786,593
Issued: November 22, 1988
Inventors: Alonzo Ross, Hilary Koprowski,
and Meenhard Herlyn
5. Monoclonal Antibodies against Melanoma-Associated
Antigens and Hybrid Cell Lines Producing
These Antibodies and Use Thereof
U.S. Patent # 4,849,509
Issued: July 18, 1989
Inventors: Jan Thurin, Hilary Koprowski,
Zenon Steplewski, and Meenhard Herlyn
6. Monoclonal Antibody to EGF Receptor
U.S. Patent # 5,470,571
Issued: November 28, 1995
Inventors: Meenhard Herlyn and Ulrich Rodeck
7. WT1 Monoclonal Antibodies and Methods
of Use Thereof
U.S. Patent # 5, 622,835
Issued: April 22, 1997
Inventors: Meenhard Herlyn, Frank Rauscher,
Ulrich Rodeck, and Jennifer Morris
8. Methods for inducing localized vascular
development and enhancing the repair of
a wound in the mammalian dermis.
U.S. Patent # 6,486,133
Issued: November 26, 2002
Inventors: Meenhard Herlyn, Mark Nesbit,
and Kapaettu Satyamoorthy